#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Familial hypertriglyceridaemia Leiomyosarcoma metastatic Hereditary optic atrophy Gaucher's disease type I Inborn error of metabolism Biotinidase deficiency Oesophageal adenocarcinoma stage II Adenovirus infection Malformation venous Gastrointestinal stromal tumour Optic glioma Glioma Rett syndrome Brain abscess Gestational trophoblastic tumour More trials…

    Learn about Rare Diseases

    Retinitis pigmentosa – Diagnostics Medulloblastoma – Diagnostics Adrenocortical carcinoma – Basic Information Rhabdomyosarcoma Piriformis syndrome – Basic Information Urea cycle disorder – Life with Disease Acquired haemophilia – Life with Disease VEXAS syndrome – Basic Information Mitochondrial myopathy – Basic Information Progressive multifocal leukoencephalopathy – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Linperlisib Sunvozertinib Carbamazepine Asciminib Ustekinumab Norepinephrine Entinostat Ieramilimab Ecoo25B Pilocarpine Hydrochloride Betula Pollen Extract Stiripentol Azd8630 Darolutamide Axatilimab Mercaptamine Ivospemin Denosumab Pyrazinamide Cipaglucosidase Alfa More therapies…

    Learn about Your Condition

    Implantation complication Ehlers-Danlos syndrome Major depression Vitamin D deficiency Adenomyosis Dry mouth Stomatitis Hypertriglyceridaemia Oedema Splenic marginal zone lymphoma Respiratory failure Infectious pleural effusion Syphilis Haemorrhage intracranial H1N1 influenza More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Haga Hospital

Haga Hospital

Els Borst-Eilersplein 275, Hague, 2545 AA, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

    Recruiting

    4 1
    Investigated Drugs:
    • LUNSEKIMIG
    Czechia Germany Greece Lithuania The Netherlands Norway +4

  • JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

    Recruiting

    3 1 1
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Teclistamab
    France Germany Greece Italy The Netherlands Norway +1

  • Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

    Recruiting

    3 1 1
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Belzutifan
    Czechia Denmark France Germany Greece Italy +3

  • A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Acalabrutinib
    • Venetoclax
    Czechia France Germany Italy The Netherlands Poland +3

  • Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Belantamab Mafodotin
    • Bortezomib
    • Carfilzomib
    France Germany Greece The Netherlands Spain

  • Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Gimeracil
    • Oteracil
    • Tegafur
    The Netherlands

  • Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Eribulin Mesylate
    • Carboplatin
    • Gemcitabine Hydrochloride
    Belgium Czechia France Germany Italy The Netherlands +2

  • A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • BLEXIMENIB
    Austria Belgium Denmark Estonia Finland Germany +8

  • A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

    Recruiting

    3 1
    Denmark France Germany Italy The Netherlands Spain

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    • RLY-2608
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Denmark France +10
1 2 3 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!